Nitrogen Attached Directly To The Piperidine Ring By Nonionic Bonding Patents (Class 514/329)
-
Publication number: 20100227885Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.Type: ApplicationFiled: April 13, 2010Publication date: September 9, 2010Inventors: David M. WEINER, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
-
Publication number: 20100221305Abstract: The invention provides for a formulation for coating one or more microprojections which reduces or minimizes the loss of counterions from the coating in order to achieve a pH-stabilized formulation.Type: ApplicationFiled: August 24, 2009Publication date: September 2, 2010Applicant: Alza CorporationInventors: Mahmoud Armeri, Wei-Qi Lin, Michel J.N. Cormier, Yuh-Fun Maa
-
Publication number: 20100222350Abstract: This invention is concerned with compounds of the formula and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.Type: ApplicationFiled: May 10, 2010Publication date: September 2, 2010Inventors: Alfred Binggeli, Andreas D. Christ, Hans P. Maerki, Rainer E. Martin
-
Publication number: 20100221313Abstract: A transdermal reservoir patch includes a first adhesive layer, a second adhesive layer and an occlusive backing layer configured to inhibit transport of a pharmaceutical agent from the first adhesive layer to the second adhesive layer. Methods of manufacturing the transdermal reservoir patch are disclosed.Type: ApplicationFiled: November 30, 2009Publication date: September 2, 2010Applicant: INNOVATIVE PHARMACEUTICALS, LLCInventors: David J. Smith, Ludwig Weimann, Ollen Williams, Jr., III, Katherine Mary Evans, Mark John Badria
-
Patent number: 7786144Abstract: The present invention relates to sulphur containing pyrazole derivatives, and their S-oxidized active metabolites, as selective cannabinoid CB1 receptor antagonists having a high CB1/CB2 receptor subtype selectivity, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of these pyrazole derivatives, to pharmaceutical compositions comprising one or more of these pyrazole derivatives as active ingredients, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.Type: GrantFiled: May 29, 2007Date of Patent: August 31, 2010Assignee: Solvay Pharmaceuticals B.V.Inventors: Josephus H. M. Lange, Cornelis G. Kruse, Bernard J. Van Vliet
-
Publication number: 20100216842Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.Type: ApplicationFiled: January 11, 2010Publication date: August 26, 2010Inventors: Kiichiro Nabeta, Toru Hibi
-
Publication number: 20100210630Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: ApplicationFiled: April 30, 2010Publication date: August 19, 2010Inventors: Damian Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, David Vogel, Guo Ping Wei, Bin Ye
-
Publication number: 20100197735Abstract: Novel phenylurea compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.Type: ApplicationFiled: March 5, 2010Publication date: August 5, 2010Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Thibaud Portal
-
Publication number: 20100196488Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.Type: ApplicationFiled: February 12, 2010Publication date: August 5, 2010Applicant: GW Pharma LimitedInventor: Brian Whittle
-
Publication number: 20100197715Abstract: The present invention relates to a compound of formula I wherein R1, R2, and Ar are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. These compounds and their pharmaceutical compositions are useful in the treatment of neurological and neuropsychiatric disorders.Type: ApplicationFiled: January 20, 2010Publication date: August 5, 2010Inventors: Sabine Kolczewski, Emmanuel Pinard, Henri Stalder
-
Patent number: 7767695Abstract: A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: GrantFiled: July 15, 2004Date of Patent: August 3, 2010Assignee: High Point Pharmaceuticals, LLCInventor: Florencio Zaragoza Dorwald
-
Publication number: 20100189778Abstract: An opioid formulation for pulmonary administration in the treatment or management of pain, a pulmonary drug delivery device containing, method of administering, kit containing, and uses of same. The formulation contains at least one rapid-onset opioid and preferably also contains a sustained-effect opioid to reduce the frequency of administration. The invention employs the side effects of the opioid formulation to permit patients to self-limit drug intake, thereby avoiding toxicity while achieving analgesia. A pharmacokinetic and pharmacodynamic model is employed to determine optimum drug formulations and optimum parameters for administration.Type: ApplicationFiled: January 15, 2010Publication date: July 29, 2010Applicant: YM BIOSCIENCES INC.Inventors: Steven Louis SHAFER, Orlando Ricardo HUNG, Diana Helen PLIURA
-
Publication number: 20100190759Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.Type: ApplicationFiled: March 30, 2010Publication date: July 29, 2010Applicant: OPKO Health, Inc.Inventors: Anandan PALANI, Xianhai HUANG, Dong XIAO, Sunil PALIWAL, Hon-Chung TSUI, Michelle Laci WROBLESKI, Ashwin U. RAO, Cheng WANG, Sapna S. SHAH, Neng-Yang SHIH
-
Publication number: 20100189793Abstract: A transdermal delivery system (TDS) for administering at least one active agent through the skin. The system has a first electrode, a second electrode, and a matrix located between the first and second electrodes. The TDS contains at least one active agent which is either alkaline or acidic. The system is configured such that when applying a voltage to the electrodes, the pH of the matrix, in the case of an alkaline active agent, does not exceed the pH of the active agent and, in case of an acidic active agent, does not fall below the pH of the active agent.Type: ApplicationFiled: December 23, 2009Publication date: July 29, 2010Applicants: ACINO AG, FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN-NUMBERGInventors: Elisabeth MEYER, Britta SCHRÕDER, Christine ZOGLMEIER, Ulrich NICKEL
-
Publication number: 20100190829Abstract: Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.Type: ApplicationFiled: June 20, 2008Publication date: July 29, 2010Inventors: John J. Baldwin, Salvacion Cacatian, David A. Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Alexey V. Ishchenko, Lanqi Jia, Gerard McGeehan, Robert D. Simpson, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Wei Zhao
-
Publication number: 20100179119Abstract: Novel compounds inhibiting the integrin ?2?1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin ?2?1/GPIa-IIa-mediated activity.Type: ApplicationFiled: September 24, 2009Publication date: July 15, 2010Inventors: William F. DeGrado, Meredith W. Miller, Sandeep Basra, Joel S. Bennett, Sungwook Choi
-
Publication number: 20100178331Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising: a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties; and a physiologically active substance.Type: ApplicationFiled: December 25, 2007Publication date: July 15, 2010Inventors: Ryoichi Nagata, Shunji Haruta
-
Publication number: 20100172974Abstract: Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.Type: ApplicationFiled: March 12, 2010Publication date: July 8, 2010Inventors: Benjamin Oshlack, Mark Chasin, Hua-Pin Huang
-
Patent number: 7750012Abstract: The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.Type: GrantFiled: August 3, 2006Date of Patent: July 6, 2010Assignee: deCODE genetics ehfInventors: Vincent Sandanayaka, Jasbir Singh, Li-Ming Zhou, Mark E. Gurney
-
Publication number: 20100168108Abstract: Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, and as an appetite stimulant.Type: ApplicationFiled: January 18, 2010Publication date: July 1, 2010Applicant: Adolor CorporationInventors: Roland E. Dolle, Karin Worm, Q. Jean Zhou
-
Publication number: 20100166889Abstract: The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: LCS GROUP, LLCInventor: Louis Sanfilippo
-
Publication number: 20100166674Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: ApplicationFiled: December 18, 2009Publication date: July 1, 2010Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20100160305Abstract: 3,4,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4,5-substituted piperidine compound, a method for the manufacture of a 3,4,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds are of the formula I, wherein the substitutents are as defined in the specification.Type: ApplicationFiled: March 7, 2006Publication date: June 24, 2010Applicant: NOVARTIS AGInventors: Keiichi Masuya, Fumiaki Yokokawa, Osamu Irie, Atsuko Nihonyanagi, Takeru Ehara, Kazuhide Konishi, Takanori Kanazawa, Masaki Suzuki
-
Publication number: 20100152242Abstract: A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. At least one of the anode and the cathode includes an electrode and a reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes (i) a drug or an electrolyte salt or a mixture thereof, (ii) propylene glycol, and (iii) an antimicrobial agent in an amount sufficient to inhibit microbial growth in the aqueous medium. The propylene glycol prevents the antimicrobial agent from being adsorbed by other materials used in the construction of the delivery device. A process for preparing a transdermal electrotransport drug delivery device is also provided.Type: ApplicationFiled: February 24, 2010Publication date: June 17, 2010Applicant: ALZA CorporationInventors: Wendy A. Young, Michel J.N. Cormier
-
Publication number: 20100144792Abstract: The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction.Type: ApplicationFiled: April 18, 2008Publication date: June 10, 2010Applicants: SENJU PHARMACEUTICAL CO., LTD., ASTELLAS PHARMA INC.Inventors: Chiho Yabuta, Fumiko Yano, Mitsuyoshi Azuma
-
Patent number: 7728008Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.Type: GrantFiled: June 26, 2006Date of Patent: June 1, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Jennifer Qiao, Tammy C. Wang, James C. Sutton, Timur Gungor
-
Publication number: 20100129443Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.Type: ApplicationFiled: December 3, 2007Publication date: May 27, 2010Inventor: Anders Pettersson
-
Publication number: 20100113396Abstract: Composition and methods of treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans.Type: ApplicationFiled: November 3, 2009Publication date: May 6, 2010Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Anil Gulati
-
Publication number: 20100112064Abstract: The invention relates to a transdermal therapeutic system which comprises a back layer that is impermeable to the active substance, and a peelable protective layer that is impermeable to the active substance and at least one matrix layer consisting of polysiloxanes and/or polysiloxane derivatives and containing micro-reservoirs. Said micro-reservoirs contain at least one ion pair from a pharmacologically active substance and an additive and either the active substance is nucleophilic and the additive is electrophilic or the active substance is electrophilic and the additive is nucleophilic.Type: ApplicationFiled: November 16, 2007Publication date: May 6, 2010Applicant: LTS Lohmann Therapie-Systems AGInventors: Thomas Hille, Michael Horstmann, Walter Mueller
-
Publication number: 20100099703Abstract: The present invention relates to phenylamino-substituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.Type: ApplicationFiled: October 31, 2007Publication date: April 22, 2010Inventors: Mónica Garcia-López, Josep Mas-Prio, Antonio Torrens-Jover
-
Publication number: 20100093800Abstract: Disclosed is drug delivery for facilitating medical and/or procedures that are performed without “general anesthesia,” which is also described in the specification as the state of patient “unconsciousness” resulting from a drug administered by an anesthetist or anesthesiologist. Mixtures of sedative and analgesic drugs are adapted for safe and effective administration by devices to provide and maintain drug infusions that do not push the patient into unconsciousness and/or general anesthesia. Drug delivery devices are also disclosed that include the use of stored parameters and/or values that correlate to drug mixture delivery during a procedure, and a patient health monitor to measure and send signals regarding a patient health condition to a processor.Type: ApplicationFiled: September 4, 2009Publication date: April 15, 2010Applicant: Scott Laboratories, Inc.Inventor: Randall S. HICKLE
-
Publication number: 20100087485Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.Type: ApplicationFiled: December 9, 2009Publication date: April 8, 2010Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Thomas Luebbers, Fabienne Ricklin
-
Publication number: 20100080829Abstract: The present invention relates to a new lyophilized pharmaceutical composition capable of adhering to oral mucosal tissue for an extended period of time for delivering active pharmaceutical ingredient through the oral mucosal tissue using transmucosal absorption.Type: ApplicationFiled: October 1, 2009Publication date: April 1, 2010Applicants: CEPHALON FRANCE, CEPHALON, INC.Inventors: Claire Dulieu, Steve Durfee, Richard J. Holl, Tam Nguyen
-
Publication number: 20100081692Abstract: The invention provides 1-benzyl-4-piperidinamines of the general formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma. The compounds are inhibitors of the CCR1 receptor.Type: ApplicationFiled: October 31, 2006Publication date: April 1, 2010Applicant: ASTRAZENECA ABInventors: Martin Hemmerling, Nafizal Hossain, Svetlana Ivanova, Tesfaledet Mussie, Igor Shamovsky, Asa Sjoholm Timen
-
Patent number: 7683079Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.Type: GrantFiled: December 14, 2005Date of Patent: March 23, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Thomas Luebbers, Fabienne Ricklin
-
Publication number: 20100068250Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.Type: ApplicationFiled: November 19, 2009Publication date: March 18, 2010Applicant: Travanti Pharma Inc.Inventors: Carter R. Anderson, Russell L. Morris
-
Publication number: 20100068249Abstract: The present invention comprises a transdermal dosage form comprising an active agent component having a skin contacting surface, an adverse agent component, and a barrier. The dosage form comprises at least one channel passing between proximal and distal surfaces of the active agent component. The barrier is interposed between the active agent component and the adverse agent component. In one aspect, the barrier is permeable to selected solvents and impermeable to diffusion of active and adverse agents in the absence of said solvent. In another aspect, the barrier is discontinuous, impermeable to diffusion of active and adverse agents, and the dosage form comprises at least one channel passing between the skin-contacting surface and the adverse agent component.Type: ApplicationFiled: November 19, 2009Publication date: March 18, 2010Inventors: John R. Hart, Steven C. Anderson, Melissa A. Vanblaricom, Ellen R. Bosl
-
Publication number: 20100069438Abstract: Disclosed herein is a combination drug designed for use by anesthesiologists for the purposes of inducing and/or maintaining general anesthesia and minimizing the stress response to pain that results from the noxious stimuli associated with surgical procedures. The present invention is suitable for use in general anesthesia to decrease the need for muscle relaxant administering and permit patients to drive themselves home after receiving the anesthetic. This invention includes a combination drug comprised of propofol (2,6-diisopropylphenol) and remifentanil (N-phenyl-N-(4-piperidinyl)amides) in which the preferred embodiment contains 2 mcg of remifentanil for each 1 mg of propofol. The combination drug invention may include a package as two drugs of proper proportions shipped and sold in a two compartment vial or syringe for mixing immediately prior to use. Alternatively, the invention may comprise a single drug prepared with proper preservatives in an aqueous solution.Type: ApplicationFiled: September 15, 2006Publication date: March 18, 2010Applicant: SCOTT LABORATORIES, INC.Inventor: Randall S. Hickle
-
Publication number: 20100063030Abstract: The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1, R2, Z and m are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.Type: ApplicationFiled: April 8, 2008Publication date: March 11, 2010Applicant: Purdue Pharma L.P.Inventors: Donald J. Kyle, Jiangchao Yao
-
Publication number: 20100063583Abstract: Disclosed herein are compositions and methods for treating inflammatory vascular diseases. Examples of inflammatory vascular disease include, but are not limited to, in-stent stenosis, coronary arterial diseases (CAD), angina, acute myocardial infarction, acute coronary syndrome, chronic heart failure (CHF), peripheral arterial occlusive diseases (PAOD), critical limb ischemia (CLI), cardiac, kidney, liver and intestinal ischemia, renal failure, cardiac hypertrophy, atherosclerosis, abdominal aortic aneurysm, vasculitis, carotid artery stenosis.Type: ApplicationFiled: August 14, 2009Publication date: March 11, 2010Inventors: Yi-Xin Wang, Le-Ning Zhang, Gabor M. Rubanyi
-
Publication number: 20100056497Abstract: The present invention relates to a compound of the formula (I) being useful as a renin inhibitor, or a pharmaceutically acceptable salt thereof. wherein R1a is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; R1b is an optionally substituted C1-6 alkoxy, etc.; R1c is a hydrogen atom, an optionally substituted C1-6 alkoxy, etc.; R2 is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and each is a group of the formula: -A-B (in which A is a single bond, —(CH2)sO—, —(CH2)sN(R4)CO—, etc., B is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.), etc.; R4 is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; s is 0, etc.; and n is 1, etc.Type: ApplicationFiled: January 30, 2008Publication date: March 4, 2010Applicant: DAINIPPON SUMITOMO PHARMA CO., LTDInventors: Hiroyuki Nakahira, Yohei Ikuma, Nobuhisa Fukuda, Tomonori Kobayashi, Shinya Tosaki
-
Publication number: 20100056554Abstract: The present invention concerns a needle-less drug delivery device being suitable for delivering drugs through a skin surface into a human or animal body comprising a pharmaceutical composition with at least one analgesic agent preferably being an opioid. The present invention also relates to the use of at least one analgesic agent, preferably being at least one opioid in a needle-less drug delivery device being suitable for injecting medication through a skin surface into the human or animal body. Further, the invention is concerned with a method of treating breakthrough pain by injecting at least one analgesic agent preferably being an opioid into the human or animal body using a needle-less drug delivery device.Type: ApplicationFiled: August 29, 2007Publication date: March 4, 2010Inventor: Jo Woodward
-
Publication number: 20100047196Abstract: Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.Type: ApplicationFiled: November 20, 2007Publication date: February 25, 2010Inventors: Andrzej Lipkowski, Anna Grabowska, Katarzyna Kurzepa, Aleksandra Szczucinska
-
Patent number: 7659287Abstract: Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:Type: GrantFiled: May 31, 2007Date of Patent: February 9, 2010Assignee: Amgen Inc.Inventors: Jay P. Powers, Yosup Rew, Xuelei Yan
-
Publication number: 20100022595Abstract: The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.Type: ApplicationFiled: April 13, 2007Publication date: January 28, 2010Applicant: Purdue Pharma L.P.Inventors: Zhengming Chen, Khondaker Islam, Donald J. Kyle, Deyou Sha, Bin Shao, Jiangchao Yao, Xiaoming Zhou
-
Publication number: 20100015183Abstract: The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.Type: ApplicationFiled: July 23, 2007Publication date: January 21, 2010Applicant: Bio Delivery Sciences International ,Inc.Inventors: Andrew Finn, Niraj Vasisht
-
Publication number: 20100016365Abstract: The present invention relates to new substituted 4-amino-piperidine opioid receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: July 17, 2009Publication date: January 21, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7649000Abstract: Compounds of general formula 1, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from H, lower alkyl, R4—CO, R4—O2CCH2, R5—OCO and R5—SO2; R2 is selected from lower alkyl, cycloalkyl optionally substituted with an alkyl or alkyloxy group, (C5-C12)cycloalkylalkyl optionally substituted with an alkyl or alkyloxy group, aralkyl optionally substituted with up to three groups chosen from F, Cl, Br, I, OH, lower alkyl, O-(lower alkyl), O-benzyl, NH2, NO2, NH-acyl, CN and CF3, and aralkyloxymethyl optionally substituted with up to three groups chosen from F, Cl, Br, OH, lower alkyl and O-(lower alkyl); or R1 and R2 together are an o-xylylene group optionally substituted on the aromatic ring with a group selected from F, Cl, Br, OH, lower alkyl and O-(lower alkyl); R3 is selected from H, OH and O-lower alkyl; R4 is selected from H, lower alkyl and phenyl; and R5 is selected from lower alkyl, phenyl and benzyl. The compounds are useful as pharmaceutical compositions.Type: GrantFiled: March 4, 2003Date of Patent: January 19, 2010Assignee: Vantia LimitedInventor: David Michael Evans
-
Publication number: 20100010010Abstract: Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent ?C— or ?N—; W is a divalent radical —CH?CH— or CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.Type: ApplicationFiled: September 14, 2007Publication date: January 14, 2010Applicant: CHROMA THERAPEUTICS LTD.Inventors: Alan Hornsby Davidson, David Festus Charles Moffat, Francesca Ann Day, Alastair David Graham Donald
-
Publication number: 20100003309Abstract: A method for the production fentanyl-based analgesics for their oral transmucosal administration in a candy-like dosage form, involving the dissolution of a pharmacologically accepted amount of Fentanyl citrate in purified water and the dissolution of a pharmacologically accepted dye in purified water. Mix polyalcohol sugar with purified water with a ratio polyalcohol/sugar between 17 and 19.5% by weight. Stir slowly over low heat until a liquid and smooth mass is obtained. Add sucrose to this liquid mass with a ratio liquid mass/sucrose between 65% and 67.5% by weight. Heat the mass and bring to a boil from an initial temperature of 128°-1320 C to a maximum temperature of 148°-152° C., until its water content evaporates and the weight of the mass obtained in this step reaches between 88% and 90% by weight with respect to the initial total weight of the liquid mass.Type: ApplicationFiled: July 11, 2007Publication date: January 7, 2010Inventor: Karen Elizabeth Quiroga